Strong in vitro data for GPC Biotech's satraplatin
German drugmaker GPC Biotech AG says that new preclinical data on its lead drug candidate satraplatin, presented at the 97th annual meeting of the American Association for Cancer Research in Washington, DC, "support" the clinical trials underway to explore its potential in a variety of combination therapies and cancer settings
According to in vitro data, satraplatin's active metabolite, JM118, in combination with Roche's Herceptin (trastuzumab), resulted in strong synergistic cytotoxic activity against SKBR-3 breast cancer cells. The firm currently has two Phase I trials evaluating the agent as a combination in advanced solid tumors as well as a Phase II study in metastatic breast cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze